Franz-Werner Haas, CureVac CEO (AP Images)
July 5, 2022 09:08 AM EDTUpdated 01:38 PM
Pharma
Law

Left be­hind at the Covid vac­cine start­ing line, Cure­Vac files suit against BioN­Tech over megablock­buster IP claims

John Carroll

Editor & Founder

BioN­Tech and their Big Phar­ma part­ners at Pfiz­er hand­i­ly beat Ger­many’s Cure­Vac to the mar­ket with a megablock­buster mR­NA vac­cine to fight Covid-19. But Cure­Vac …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times